Tyra Biosciences, Inc.

Fair Value Measurements The Company measures cash equivalents and available-for-sale debt securities at fair value.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Available-for-sale debt securities, including U.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Marketable Securities Marketable securities consist of debt securities of government-sponsored entities.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Premiums and discounts on debt securities are amortized or accreted into interest and other income, net.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The fair value of stock options was estimated using the following assumptions: Six Months Ended June 30, 2026 2025 Risk-free rate of interest 3.7 - 4.3 % 3.8 - 4.4 % Expected term (years) 5.3 - 6.1 5.3 - 6.1 Expected stock price volatility 72.9 - 81.9 % 86.3 - 95.4 % Dividend yield The weighted-average grant date fair value of options granted for the six months ended June 30, 2026 and 2025 was $ 23.37 and $ 8.30 per share, respectively.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.

SEC original ↗Tyra Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 14, 2025

BEACH301 is a Phase 2, multicenter, open-label, dose-escalation/dose-expansion study evaluating dabogratinib in children ages 3 to 10 with achondroplasia with open growth plates.

SEC original ↗Tyra Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 14, 2025

(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology.

SEC original ↗Tyra Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 14, 2025

The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Legal Proceedings 27 Item 1A.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Litigation The Company, from time to time, may be party to litigation arising in the ordinary course of business.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company was not subject to any material legal proceedings as of June 30, 2026 , and no material legal proceedings are currently pending or threatened.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risk factors described in Part II, Item 1A, Risk Factors of this Quarterly Report.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026

New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

SEC original ↗Tyra Biosciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026